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Summary: 
 
Despite 100 years after the discovery of thyroxine, controversy still exists regarding optimal 
thyroid hormone replacement therapy. Several anecdotal reports suggest that thyroxine alone 
therapy does not normalise psychological wellbeing. My cross-sectional study (n=1922) 
provided the first evidence in support of the hypothesis that a small proportion of patients on 
thyroxine alone therapy have increased psychological morbidity despite having normal TSH 
(publication 1). My second study was the largest randomised placebo controlled study to date 
to compare the effects of thyroxine alone and combined T3/T4 therapy over a 12 months 
period. This categorically proved that thyroxine alone therapy should be the first choice for 
hypothyroid patients (publication 2). Further genetic analysis of the deiodinase genes showed 
that a sub-group of hypothyroid patients with an SNP on D2 gene do have reduced 
psychological wellbeing on thyroxine alone therapy and improve on combined T3/T4 therapy 
compared to those without (publication 5). Both these findings were shown only by our study 
and were possible because of the large size (n=700). Detailed analysis of the various thyroid 
hormones and their ratio from our study showed that in addition to TSH, free T4 should be 
taken into account when treating hypothyroid patients (publication 4). My pharmacokinetic 
study provided the crucial and first evidence of the profiles of thyroid hormones on once a day 
combined T3/T4 therapy, highlighting the need to use either slow-release T3 or multiple doses 
of T3 in a day (publication 3). Our invited commentary and review (publications 6-8 & 10) have 
highlighted the importance of “individualised set points” for thyroid hormones, the complexity 
of thyroid hormone transport and actions as well as an algorithm for approaching hypothyroid 
patients. My other work (publication 9) was the first to test the possibility and provided the first 
evidence of deiodinase gene polymorphisms affecting circulating thyroid hormone levels and 
their possible role in psychological wellbeing in normal population. Thus, my work in the area, 
“Psychological wellbeing in patients of thyroid hormone replacement therapy” has provided 
several landmark findings, resulting in 10 publications including 4 in JCEM, 2 in Lancet and 1 
in Clinical Endocrinology. 
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Background: 
 
Up to 3% of general population are on thyroid hormone replacement therapy in the western 
countries (1). The most common indication for such replacement therapy is primary 
hypothyroidism (2), but in a significant number of individuals thyroid hormone replacement 
follows destructive therapy for hyperthyroidism, nontoxic goitre or thyroid cancer with either 
radioactive iodine (RAI) or surgery. Autoimmune thyroid disease is one of the commonest 
endocrine disorders affecting up to 10% of general population in iodine-sufficient countries. Of 
these, around 1-3% has overt hypothyroidism and the remaining has untreated subclinical 
hypothyroidism (3-5).  
 
A normally functioning thyroid gland produces both thyroxine (T4) and tri-iodothyronine (T3), 
containing 4 and 3 iodine atoms respectively. A majority of the thyroid hormone production is 
in the form of T4. Thyroxine does not have direct action on the tissues and has to be 
converted to T3, by deiodination, which acts on the thyroid hormone receptor (THR). Out of 
the daily requirement of T3 (around 30 mcg), approximately 24 mcg is generated by peripheral 
deiodination of T4 and the remaining 6 mcg is produced directly by the thyroid gland. Such 
deiodination is carried out by not one but three selenium dependent deiodinases (D1, D2 and 
D3) each with different catalytic specificity, tissue distribution and sensitivity to extracellular 
influences. For example, tissues expressing higher concentration of D2 are more sensitive to 
circulating T4 than T3 and those with higher expression of D1 are more sensitive to T3 than 
T4. As a result, the amount of intracellular T3 derived directly from circulating T4 rather than 
T3 can vary up to 10-fold between tissues (6). Indeed, the pituitary gland has much higher 
expression of D2 making it more sensitive to circulating T4 than T3.  
 
Despite these complexities, the standard thyroid hormone replacement comprises only T4. 
This is because it has a much longer half-life and therefore can be used as once a day 
preparation. Thus, it yields more stable levels of serum T3 over 24-hours compared to T3 
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alone therapy, which has to be used 3 times a day. In addition, it was perceived that 
peripheral deiodination should provide adequate levels of T3 that is required for the tissue 
action.  
 
In the past four decades, there have been significant changes in standard practice for thyroid 
hormone replacement. In the 1960s synthetic T4 replaced the use of desiccated thyroid 
extract as the latter posed a challenge for standardization (7). Then in the 1980s, following the 
introduction of sensitive TSH assays, it became established practice to adjust the dose of T4 
to achieve a TSH level within the laboratory normal range (8). It was argued that thyroxine 
doses that normalize the TSH level must result in physiological thyroid hormone replacement 
as the hypothalamo–pituitary axis perceives such doses as satisfactory. This resulted in 
significant dose reductions for many patients, in some cases by up to 100 µg per day, to 
achieve TSH levels in the “normal range”. 
 
In recent years, however, there appears to be an increasing number of patients who express 
dissatisfaction with their thyroid hormone replacement. Subsequently, several anecdotal 
reports suggested that treated hypothyroid patients began to complain that “they do not feel 
right”, especially reporting reduced psychological wellbeing despite their biochemical 
euthyroidism – referred as “euthyroid dysphoria”. In response to our article in the newsletter of 
the British Thyroid Foundation (BTF), 204 respondents reported persisting psychological 
symptoms following treatment for thyroid disease and 54 mentioned specifically not feeling 
normal despite their thyroid function being in the laboratory normal range (9). Many patients 
also found their physicians to be unsympathetic and dismissive of their symptoms. In this 
context, Carr et al. (10) had previously observed that patients’ visual analogue scales of well-
being were highest on doses of thyroxine that resulted in low TSH levels (<0!2mU/l), doses 
that the authors considered to be 50µg higher than ‘optimal’ replacement. 
 
In response to such expressions of dissatisfaction, a group of general practitioners and private 
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practitioners have advocated titrating the dose of T4 against the clinical status of individuals 
rather than the TSH levels (11) and doubt has been cast on the true value of TSH 
measurements in patients undergoing thyroid hormone replacement (12). Some 
endocrinologists agree with a role for clinical assessment in addition to measuring TSH (13), 
though many were not convinced. There was only one small study directly compared 
symptoms in patients on thyroxine with a normal TSH and controls and no significant 
differences were observed (14). 
 
However, this is a difficult area, as many of the symptoms of hypothyroidism are nonspecific 
and could be confused with low mood, stress-related illness or depression due to other 
causes. As both depression (15, 16) and thyroid hormone replacement (2) are common in the 
general population a causal relationship between them could easily be wrongly inferred. On 
the other hand, evidence from rodent studies suggests that T4 replacement alone does not 
provide normal T3 levels in all tissues and suffer “tissue hypothyroidism” (17, 18). Indeed, as 
approximately 15% of circulating T3 in healthy human beings is produced by thyroid gland 
(rest generated peripherally from T4), and if we extrapolate the rodent data, such “tissue 
hypothyroidism” could exist in humans. This in turn could be at least one of the causative 
factors for the dissatisfaction of some of the hypothyroid patients on T4 alone replacement 
with normal TSH (“euthyroid dysphoria”). 
 
Around the time of designing our baseline study, a small study (n=33) was published in the 
New England Journal of Medicine (19) suggesting combined T3/T4 therapy (both given once a 
day) is superior to T4 alone therapy for hypothyroid patients. However, there were several 
limitations, which are described in detail later. Thus, there were several unanswered questions 
in this common endocrine problem.  
 
These were: 
1. Does “euthyroid dysphoria” exist in treated hypothyroid patients with normal TSH on 
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thyroid hormone replacement therapy (T4 alone)? 
2. Does combined T3/T4 therapy for hypothyroidism improves patients’ psychological 
wellbeing? 
3. Can adequate 24-hour thyroid hormone profiles (T4, T3 and TSH) be achieved on once 
a day T3/T4 replacement therapy? 
 
We designed our baseline study to answer the first question. To address this, and to avoid 
selection bias as far as possible, we decided to study the psychological wellbeing of patients 
on T4 in a community-based setting. This was my first project and my first published work in 
this field. 
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Commentary linking the work done: 
 
Project 1 - Cross sectional study (publication 1): 
 
Introduction:  
 
My first project was a large community based study involving 1922 patients (publication 1). As 
a first stage of this project, in collaboration with a clinical psychologist, we designed a thyroid 
symptom specific questionnaire, TSQ (thyroid symptom questionnaire). This was developed 
using the feedback from the patients for an article in the British Thyroid Foundation newsletter. 
As the symptoms of T4 under replacement are poorly defined, we chose to use the General 
Health Questionnaire-12 (GHQ-12). The GHQ-12 asks subjects to describe how they currently 
feel compared with their normal expectation and was developed to detect psychological 
distress of an unspecified nature in the general population (20, 21). It is a well-validated 
questionnaire that detects ‘caseness’ in the general population with a sensitivity of 72 – 80% 
and specificity of 75 – 86%, when compared with complex, time-consuming interviews by a 
trained psychiatrist, such as the ‘Clinical Interview Schedule and Present State Examination’ 
(22). The TSQ was developed in a similar format to the GHQ-12. A pilot study on 100 patients 
was then conducted before the large community based survey. A trend towards less 
psychological wellbeing was observed in the study group (treated hypothyroid patients) 
compared to age and sex matched control group.  
 
Methods:  
 
This pilot study enabled us to design the main study requiring a study sample of 1000 subjects 
(500 controls and 500 study). Prescribing records from five general practices in the Weston- 
super-Mare area in South West England covering a population of 63,000 were used to identify 
the patients on thyroxine. A total of 961 patients aged between 18 and 75 years and who had 
 10 
been taking thyroxine for at least 4 months were identified. Computer records were then used 
to identify a control subject from the same practice with the same age and sex as each of the 
patients. All 1922 individuals were sent the same two-page questionnaire, anticipating 50-60% 
returns.  
 
Each questionnaire was accompanied by a covering letter and a prepaid return envelope. The 
covering letter, signed by the patients’ general practitioner, explained that this was a survey 
into the ‘effects of medication on people’s general health’. It was stipulated that the completed 
questionnaires from those on no medications were also important and that the results of this 
survey will help to guide changes in the prescribing of certain medications. The first page of 
the questionnaire asked the individuals to indicate if they ever had any conditions or 
treatments from a list of 12 in order not to draw attention to just thyroid disease. These were 
as follows: diabetes, angina or heart disease, underactive thyroid disease, stroke, depression, 
radioactive iodine, high blood pressure, asthma, overactive thyroid disease, anaemia, 
epilepsy/fits and thyroid surgery. A list of present medication and doses was then requested to 
confirm that none of the controls and all of the patients were indeed taking thyroxine. This was 
also used to identify the use of psychotropic and other chronic disease medications.  
 
The second page consisted of the GHQ-12. Respondents mark each question on a four-point 
scale from ‘better than usual’ to ‘much less than usual’. Results were scored by the traditional 
bimodal GHQ scoring method (0, 0 and 1, 1) and the Likert scoring method (0, 1, 2 or 3) (20). 
The maximum score was therefore 12 with the GHQ scoring method and 36 with the Likert 
scoring method. A high score indicates high levels of dissatisfaction with the respondent’s 
current mental status. The third page consisted of our devised TSQ. Answers were scored in 
the same way as the GHQ-12. This questionnaire has not yet been validated and hence was 
not used as a primary study endpoint.  
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Results: 
 
The overall response rate was 60%. Five hundred and ninety seven patients on thyroxine 
(patient; P - 62%) and 551 controls (C 57%) responded. The responding populations were 
well matched for age (P : C = 59!96 : 59!35 years, P = 0!45) and sex (P : C = 84!7% : 87%, 
females). Though, as might be expected, the non-responders were younger than responders, 
there was no difference between the patient and control groups (non-responder P : C 56!20 
vs. 55!52 years, P = 0!94) and the sex ratio was similar (P : C = 85!2% : 84!0%, females). The 
principal reasons for taking T4 was primary hypothyroidism. Out of the 597 patients, 462 
(77!9%) had their TSH checked within the past 12 months and of these 85!9% (n = 397, nP 
group) were in the laboratory normal range (TSH – 0.2-5.5 u/l). Mean age and sex of the nP 
group were well matched to the controls (mean age nP : C = 59!73 : 59!35 years, P = 0!82, 
sex nP : C = 82!6% : 87%, females).  
 
The GHQ-12 was completed by 535 out of 551 controls and 572 out of 597 patients. For the 
TSQ the equivalent figures were 534 and 583, respectively. Using the Likert scoring method, 
the mean GHQ-12 scores were significantly higher in the P than the C group (12!09 vs. 11!39, 
P = 0!028), indicating an increased incidence of dissatisfaction with current mental status. The 
differences persisted in the nP subgroup [12!11 vs. 11!39 (all controls), P = 0!017]. With the 
TSQ, a greater difference was seen between the P and C groups (12!55 vs. 11!52, P < 
0!001), which also persisted in the nP subgroup (12!81 vs. 11!52, P < 0!001). To evaluate the 
clinical importance of these differences, the questionnaires were also scored via the ‘GHQ 
method’ and the results examined against different thresholds for “caseness”. Of the control 
group 137/398 (25!6%) scored 3 or more using the GHQ scoring method, a cut-off level (GHQ 
2/3) that has been used frequently in previous studies to indicate “caseness” (22). Using this 
threshold, a significantly higher proportion of both the total patient group and the group having 
normal TSH values would be classified as “cases” [P = 32!3% (p = 0!014), nP = 34!4% (p = 
0!005)].  
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Figure 1: Odds ratio of “caseness” in patients compared to control population 
                                  
Well-being on thyroxine 583
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et al., 1993), revealed a similar 6% point absolute increase in the
number of cases. Note that the GHQ-12 scores for the control
group in this study are comparable to those seen in females from
the British Household Panel and the Health Survey for England
(Pevalin, 2000).
The strengths of our study design include the large number of
subjects questioned, the community base (rather than selected,
‘dissatisfied’ endocrine clinic attenders), the inclusion of controls
from the same geographical population and the lack of emphasis
on thyroxine in the questionnaires. The response rate was relat-
ively high for postal surveys of this nature and the close size and
demographic similarity in the responding patient and control
populations were fortuitous.
However, this is a difficult area of study and inevitably there
are weaknesses in our data. TSH levels were not measured at the
same time as the survey was conducted and reliance was placed
on previously measured values. Although dissatisfied individuals
might have their TSH estimated more frequently, it should
be noted that similar differences in scores were seen between
the whole population and those in which the TSH levels had
been measured. The nature of the control group also deserves
comment. Although the controls were individually age- and sex-
matched to each of the patients in the population surveyed, the
responding populations inevitably contain some differences,
albeit not statistically different in this study.
It could also be argued that patients on T4 should be compared
to controls on comparable chronic medication or with an un-
related chronic disease. However, selecting such a population
Table 4 Comparison of GHQ and TSQ results (‘GHQ scoring method’) between patients and controls after correcting for confounding factors. The 
percentage of responders with total GHQ or TSQ scores above the threshold for caseness shown in the left-hand column is indicated. n refers to the number 
in each group responding with completed questionnaires. Controls, all controls; P, all patients; nP, patients with TSH in local laboratory normal range; 
nP!, patients with TSH in narrow normal range (0·4–4·0 mU/l). Note that numbers are slightly different for GHQ and TSQ as some responders only 
fully completed one questionnaire. Right-hand three columns show P-values for comparison between total control group and P, nP or nP! groups after 
correction for age, sex, chronic disease and chronic medication use by multiple regression analysis. Odds ratio (OR) and 95% confidence intervals are 
shown below each figure
% Distressed Significance (P) Controls vs.
Controls All Patients (P) Patients (nP) Patients (nP!) All Patients (P) Patients (nP) Patients (nP!)
n = 535 n = 572 n = 381 n = 296
GHQ " 3 25·6 32·3 34·4 35·1 0·031 
OR 1·35 
(1·03–1·78)
0·012 
OR 1·48 
(1·09–2·00)
0·008 
OR: 1·56 
(1·13–2·15)
GHQ " 4 19·1 25·0 26·2 26·0 0·039 
OR 1·37 
(1·02–1·85)
0·024 
OR 1·46 
(1·05–2·03)
0·032 
OR 1·47 
(1·03–2·10)
n = 534 n = 583 n = 389 n = 305
TSQ " 3 35·0 46·8 48·6 48·5 < 0·001 
OR 1·59 
(1·24–2·04)
< 0·001 
OR 1·71 
(1·29–2·25)
< 0·001 
OR: 1·73 
(1·28–2·32)
TSQ " 4 24·9 37·2 39·1 40·3 < 0·001 
OR 1·77 
(1·35–2·32)
< 0·001 
OR 1·90 
(1·41–2·55)
< 0·001 
OR: 2·04 
(1·48–2·80)
TSQ " 5 17·6 25·9 26·5 27·2 0·002 
OR 1·60 
(1·19–2·17)
0·005 
OR 1·61 
(1·16–2·25)
0·003 
OR: 1·70 
(1·20–2·42)
Fig. 3 Odds ratios and confidence intervals for casenesss (GHQ) 
comparing the patients and patient subgroups with normal TSH to 
controls. The Y-axis shows odds ratios for caseness using GHQ scores 
of 3 or more as a threshold. The X-axis shows groups compared with 
the control group: total responding patient group (P), patient group with 
TSH in normal laboratory range (nP) and patient group with TSH in a 
narrow normal range (0·4–4·0 mU/l; nP!).
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Figure 1: Odds ratios and confidence intervals for caseness (GHQ) comparing the patients and patient 
subgroups with normal TSH to controls. The Y-axis shows odds ratios for caseness using GHQ scores 
of 3 or more as a threshold. The X-axis shows groups compared with the control group: total 
responding patient group (P), patient group with TSH in normal laboratory range (nP) and pa ient group 
with TSH in a narrow normal range (0!4–4!0 mU/l; nP"). 
 
These differences persisted even after correction for age, sex, general pra tice, chronic 
disease and chronic drug use. Similar but somewhat greater differences were seen using the 
GHQ method to score the TSQ. Repeat analysis of the data using a subgroup of patients 
whose TSH values fell into a narrower normal range (TSH = 0!4 – 4!0 mU/ l, n = 296, nP*) 
gave similar, if not worse results. 
 
Summary & significance of this publication:  
 
Thus, the results show that patients on thyroxine with “normal” TSH had significantly 
increased  morbidity compared to their age, sex and GP practice matched controls. Indeed, 
we identified a 6.7% (25.6% vs. 32.3%) absolute increase in  caseness (odds ratio of 1.35-
1.56) in patients on T4 with a TSH in the normal range compared with a matched control 
group. Such an increase, if true, could account for nearly 50,000 excess  cases in the United 
Kingdom. This study had unique strengths, being the first to systematically study the 
psychological wellbeing in a large number of patients that is community-based, assessing 
everyone on thyroxine rather than a sub-group of patients recruited from secondary care (self-
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presenting to specialists). This was the first hard evidence that hypothyroid patients on T4 
treatment do suffer from increased morbidity despite having their TSH in the normal range. 
However, this did not prove a causal effect. This resulted in my second project. 
 
Project 2 – Prospective Randomised Placebo-Controlled Trial (publication 2): 
 
Introduction:  
 
My first project, the cross-sectional study, confirmed that there is strong association between 
treated hypothyroid patients and reduced psychological wellbeing. This supports the 
hypothesis, “similar to animals, relative tissue hypothyroidism on T4 alone therapy may be 
present in humans causing hypothyroid symptoms related to certain tissues and cause 
reduced wellbeing”. However, it is not known whether combined T3/T4 replacement therapy 
(mimicking the normally functioning thyroid gland) corrects or improves the psychological 
wellbeing of the hypothyroid patients who are on adequate replacement of T4 judged by their 
TSH. Such improvement will confirm any such association is causal. There was increasing 
evidence from animal studies around the time of our cross-sectional study suggesting such 
association may indeed be causal. A series of elegant studies from Escobar-Morreale showed 
that unless the combination of T3/T4 is used for replacement in hypothyroid rats, several 
tissues lack adequate T3. However, evidence from humans was limited. The T3/T4 ratios are 
lower in hypothyroid patients on T4 alone therapy than those with endogenous thyroid function 
(23). This suggests some tissues especially the ones relying on circulating T3 may indeed 
have lower intracellular levels of T3 than required. The only clinical evidence to support the 
role of combined T3/T4 therapy came from a small study on 33 post thyroid cancer patients 
over 5 weeks showing the patients preferred combined T3/T4. However, there were several 
limitations of this study: 1) small number of highly selected patients who had thyroidectomy for 
previous thyroid cancer; 2) short duration (5 weeks of intervention); 3) no washout period 
during the crossover design and 4) use of a visual analogue scale that was not validated. To 
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resolve this issue, my second project was designed to test the effect of combined T3/T4 
therapy for hypothyroid patients on adequate T4 only replacement (as per their TSH). Using 
the data from the cross-sectional study, we carefully powered and designed a large double 
blind, community based, randomised placebo controlled trial comparing the effects of T4 alone 
vs. combined T3/T4 therapy. This was the largest (n=697) and of the longest duration (12 
months) in the world to date testing the effects of combined T3/T4 therapy for hypothyroid 
patients (publication 2). 
 
Methods:  
 
A sample size of 700 patients was needed based on our cross-sectional study data to detect a 
0.7-point difference between the groups on the GHQ-12 Likert scale with 80% power at a 
significance level of 0.05. Potentially eligible subjects were recruited from 28 GP practices in 
the Bristol and Weston-super-Mare area, West of England, United Kingdom. Patients between 
18 and 75 years of age on T4 dose of more than 100 mcg/d and their dose not adjusted for 3 
months with a normal TSH level recorded in the last 15 months were included in the study. 
Those with a history of myocardial infarction, unstable angina or heart failure in the previous 3 
months, thyroid cancer or secondary hypothyroidism, concomitant cholestyramine use, use of 
antidepressants in the previous 3 months or amiodarone in the previous 12 months were 
excluded. At randomization, patients T4 dose was reduced and substituted either by identical 
looking 10 mcg of T3 (T3/T4 group) or 50 mcg of T4 (placebo/T4 alone group). The remaining 
T4 dose (original dose minus 50 mcg) was given in open-label packs. Thus, in the combined 
T3/T4 group 50 mcg of T4 was substituted by 10 mcg of T3. Patients were assessed at 3 
months (visit 2) and 12 months (visit 3). The following physical measurements were taken at 
each visit: weight, electrocardiogram, blood pressure (twice at 10-min intervals), resting pulse 
rate, and body composition. The patient’s psychological well-being was assessed by the 
following scales: the GHQ-12, TSQ, the Hospital Anxiety and Depression questionnaire 
(HADS), and 23 visual analog scales of mood, cognitive behavior, and physical symptoms 
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used in the study of Bunevicius et al. (19). In addition, patients completed a satisfaction 
question on a five-point scale and a sleep and neuromuscular symptoms questionnaire. A 
serum sample was taken at baseline and 24-h post thyroid hormone dose (visits 2 and 3) for 
the following estimations: creatinine kinase, total cholesterol, alkaline phosphatase, calcium, 
free T3, free T4, TSH, SHBG and antithyroid peroxidase (anti- TPO) antibodies. Samples for 
thyroid function and SHBG from all three visits were analyzed together. The GHQ-12 and the 
TSQ were scored both by the Likert method (0–3 per question, maximum score 36-most 
dissatisfied, linear method) and by the GHQ method (0, 0, 1, 1, maximum score 12-most 
dissatisfied) to assess “caseness” (using a threshold score of 3 or more, categorical method). 
The changes in the GHQ-12 scores at 3 months, controlling for baseline scores, represented 
the primary outcomes. The secondary endpoints were changes in TSQ at 3 months as well as 
both the GHQ and TSQ scores at 12 months. The other secondary endpoints were the 
changes HADS, visual analogue scales, sleep and neuromuscular symptoms questionnaires 
and various biochemical markers are all used secondary endpoints. Results were analyzed by 
intention to treat. The last observation was carried forward to replace missing values at 3 
months and at 12 months follow-up if the patients were withdrawn from the study. 
 
Results:  
 
Out of the 37 GP practices contacted, 28 expressed interest in taking part in the study. Of the 
initial 3621 on T4, 1868 patients were contacted after the inclusion and exclusion criteria. 
1460 replied, and 1014 showed interest in taking part in the study. On further telephone 
screening and records review, 242 of these patients were excluded, mainly due to abnormal 
TSH or recent use of antidepressants. Of the 772 finally attended the screening visit, 697 
patients were randomized.  
 
Baseline characteristics were similar between the two groups including the TSH, Free T4 and 
Free T3 levels. Baseline free T4 levels (20.99 +/- 3.66 pmol/liter) were in the upper part of the 
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reference range (10.0 –24.0 pmol/l) whereas free T3 levels (3.85 +/- 0.7 pmol/ liter) were in 
the lower part of their reference range (2.8–7.1 pmol/liter). Nearly 95% were followed up at 3 
months (primary end point) and 88% at 12 months. Three months after intervention, the mean 
free T4 in the T3/T4 group had fallen from the upper part to the lower part of the reference 
range and was significantly lower than in the T4 alone group [(13.73 vs. 19.59 pmol/liter), 
p<0.001]. Mean basal free T3 levels were unchanged in both groups, but a 132% rise in 
median TSH was seen in the T3 group (2.28 vs. 0.728 U/l, p<0.001).  
 
Figure 2: Thyroid hormone levels at baseline, 3 and at 12 months 
the estimated risk reduction attributable to the intervention
was 0.61 with a CI that did not include zero (0.42, 0.90), and
there was also a significant improvement in the HADS anx-
iety score (OR, 0.55; CI, 0.32, 0.95). However, no difference
in psychological well-being was detected using the HADS
depression score, visual analog scales of mood, cognitive
behavior or physical symptoms, a satisfaction questionnaire,
or our TSQ. In addition, the differences in GHQ caseness and
HADS anxiety were not apparent after 12 months. Taken
together, these results suggest that if there is a benefit from
the intervention, it is easily overwhelmed by the size of the
placebo effect and is insufficient to completely correct the
difference between patients on T4 and age-matched controls
seen in the cross-sectional study used to power the trial.
Our protocol was designed to maximize sample size and
contains several potential limitations. Firstly, the use of a
fixed substitution of 50 !g T4 with 10 !g T3 resulted in a rise
in TSH and a fall in T4 to the low reference range in the
intervention group indicating underreplacementwith T4. Be-
cause tissues derive up to 50% of their intracellular T3 di-
rectly from serum T4, this may have reduced the benefit
gained in the intervention group and underlines the impor-
tance of replacing both T3 and T4 appropriately. Secondly,
despite limiting study entry to patients on "100 !g of T4
(average daily dose 124.3 !g), many of the subjects with
primary hypothyroidism in the trial may have had residual
thyroid function. This, in combination with the use of a fixed
T3 to T4 substitution ratio, might be expected to result in
further variability in achieving optimal final T3 and T4 levels
in subjects after intervention. Thirdly, the timing of the base-
line (visit 1) blood sample was not controlled, whereas the 3-
and 12-month samples were taken 24 h postdosing with
thyroid hormone. This may underlie the apparent fall in FT4
levels between baseline and 3months in the T4 group despite
a fall in TSH because TSH levels are much less dependent on
dose timing over the 24-h period (29). Fourthly, as with
previous studies, multiple psychological scales were used,
increasing the possibility of positive findings by chance in
one or more or the measures. However, primary and sec-
ondary analyseswere defined in advance both in terms of the
parameters to be analyzed and the primary outcome time
point. For this reason, formal statistical correction was not
made in reporting the results of the secondary analyses.
There have now been six other reported studies of the use
of T3 and T4 in combination including the original report of
Buneuvicius et al. (17–22). All used different T4 reduction/T3
substitution regimes, some using a crossover design and
apart from the original report showed either no benefit (18–
21) or a worsening of well-being (22) even when a subgroup
of dissatisfied patients was examined (22). The major differ-
ence with the current report was in the number of partici-
pants. Calculations on the basis of the differences seen in our
previous cross-sectional study resulted in the current study
being over 6 times larger than any of the other studies (n !
23–101). Even on this basis, we were somewhat optimistic in
powering the study to detect only a difference equal to or
greater than the whole difference between the groups in our
cross-sectional study; indeed, the observed difference was
FIG. 2. TSH, free T4, and free thyroid hormone levels at 0, 3, and 12 months. Median levels of TSH are shown. For conversion into SI units,
multiply by: T3, 15.55; T4, 12.87
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Figure 2: TSH, free T4, and free thyroid hormone levels at 0, 3, and 12 months. Median levels of TSH 
are shown. For conversion into SI units, multiply by: T3, 15.55; T4, 12.87 
 
Though this was initially surprising, our pharmacokinetic sub-study (publication 3, discussed 
later) revealed the reasons behind such a raise in TSH.  
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At 3 months, the GHQ scores by the Likert method improved markedly in both the placebo (T4 
alone) and the intervention (T3/T4) groups compared with baseline (baseline to 3 months: T4 
alone, 13.48–11.13, p<0.001; T3/T4 group, 13.42–10.67, p<0.001) with a 39% relative 
improvement in  caseness in the placebo group (43.9% to 26.6%). These changes are 
consistent with a marked placebo effect, although improved compliance with medication in the 
placebo group as evidenced by a significant fall in the serum TSH levels (baseline to 3 
months: T4 alone, 0.94 – 0.728 U/l, p<0.05) could have contributed.  
 
Figure 3: Change in GHQ Likert scores and % caseness by GHQ categorical scores 
Fig 3a        Fig 3b 
only around 60%of this (0.43 vs. 0.7 points on theGHQLikert
score). It remains possible that optimized replacement with
T3 and T4 could improve well-being in a small subgroup of
patients, but clear predictive markers would be required to
help distinguish this group from the changes due to placebo
and to guide the design of future studies. Our observation
FIG. 3. Relationship between baseline TSH and free T3 and free T4 levels. T3 and T4 levels are expressed as SD scores to enable comparison
of gradients. Regression coefficient (b) with 95% CI is expressed at the bottom of each figure. Left, a, Relationship using all the 697 observations.
Right, b, Relationship after removing six outlying observations. The circles indicate the observations removed. Note that the x-axis scale in b
is different from a, but the same between the two parameters (T3 and T4) to enable visual comparison of gradients.
FIG. 4. Comparison of outcomes. Likert score on the GHQ at 0, 3, and
12 months. T3, Combined T3 and T4; T4 alone, placebo.
FIG. 5. Comparison of primary outcomes. Caseness according to the
GHQ at 0 and 3 months. Percentages of cases are shown above the
bars.
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Figure 3a: Likert score on the GHQ at 0, 3, and 12 months. T3, Combined T3 and T4; T4 alone, 
placebo. 
Figure 3b: Caseness according to the GHQ at 0 and 3 months. Percentages of cases are shown above 
the bars. 
 
Comparisons between the groups revealed a difference of 0.47 points in the GHQ scored by 
the Likert method, which was smaller, than the difference used to power the trial (0.7) and did 
not reach significance at the p<0.05 level (95% CI, 0.26, 1.12; p=0.218). Using the categorical 
scoring methods with a threshold 2/3, a significantly greater reduction in  caseness was seen 
in the T3/T4 group compared with T4 alone [19.2 vs. 26.6%, odds ratio (OR), 0.61; 95% CI, 
0.42, 0.90; p<0.01). Improvement was also seen in the HADS anxiety score at 3 months (OR, 
0.55; 95% CI, 0.32, 0.95; p<0.033). However, no difference was seen in the TSQ scores, 
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sleep, neuromuscular symptoms, HADS depression category, or visual analog scales, and the 
percentage of patients reporting that they felt better on direct questioning were not different. 
No significant differences were seen in any of the physical or biochemical measures other 
than a slightly lower diastolic blood pressure in the T4 alone group. The significance of these 
results was unchanged when controlled for age, sex, type of diagnosis, pre-study T4 dose, 
use of other chronic medication, baseline GHQ scores, anti-TPO positivity, and baseline 
thyroid function (free T3, free T4, TSH, and T3 to T4 ratio). 
 
When the subjects were reassessed at 12 months, GHQ scores in the intervention group (T3) 
had risen (worsened, p=0.0034), and there was now no difference between the two groups 
(T3 vs. T4 alone, p=0.24). Interestingly, in both groups, the free T3 to T4 ratio fell significantly 
(T3 group, 9% reduction; T4 alone group, 6% reduction, both p<0.001) between 3 and 12 
months. No change was seen in TSH levels over this period. 
 
Summary & significance of this publication: 
 
The results from this large community-based study categorically confirmed that for majority of 
hypothyroid patients T4 alone is the first choice thyroid hormone replacement. It did not 
provide conclusive evidence of specific benefit for all the patients on a fixed dose combined 
T3/T4 therapy over a 12-month period but showed possible benefits at 3 months. It remains 
possible that a small subgroup of individuals does benefit specifically from partial substitution, 
but parameters identifying such a group have yet to be clearly identified. In addition, this study 
showed several other important observations. Firstly, this study confirmed the observations of 
the cross sectional study that significantly increased psychological morbidity is observed in 
treated hypothyroid patients with normal TSH. Secondly, it showed that the pituitary gland is 
more sensitive to T4 than T3 (as observed by raise in TSH levels and fall in T4 levels in the 
T3/T4 group). Thirdly, contrary to belief, placebo effects can last for at least 12 months. 
Though the T3/T4 group were marginally better at 3 months, their wellbeing stayed at the 
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same level between 3 and 12 months. However, the T4 alone group continued to get better 
and were exactly the same as the T3/T4 group. Fourthly, the study group were better both at 3 
and 12 months despite significantly higher TSH (more than 135%) suggesting a possible 
independent effect of T3. This also confirms the hypothesis that different tissues respond 
differently to T4 and T3 levels. Finally, the similar pre-dose T3 levels observed between the 
T3/T4 and T4 alone group, raising questions about adequacy and duration of action of T3 in 
the T3/T4 group. This was addressed in my third project – “Thyroid hormone profile study” 
(publication 3). In order to identify a potential sub-group of patients who may respond 
differently to T4 alone and combined T3/T4 therapy, the DNA samples collected from this 
study were utilised to identify potential polymorphisms of the deiodinase enzymes and their 
correlation with well being (publication 4). 
 
Project 3 – 24-hour profiles of thyroid hormones on combined T4/T3 therapy 
(publication 3): 
 
Introduction: 
 
Similar to our study, around the same time, six other studies were published on combined 
T3/T4 therapy. Five showed no benefit (24-28) and one showed patient preference for 
combined T3/T4 replacement (29). However, combined T3/T4 therapy is still widely used (30, 
31) as once a day T4 and T3. Careful pharmacokinetic studies performed nearly 30 years ago 
showed that T3 if used as monotherapy for hypothyroidism, should be given at least three 
times a day to have a smooth 24-Hour profile of T3 (32). They also showed that thyroid 
hormone levels were stable over the 24-hour period on once daily T4 monotherapy. At the 
time of designing our pharmacokinetic sub-study, there was no evidence to show the 24-hour 
profiles of thyroid hormones on combined T3/T4 therapy. T4 has a half-life of 5-7 days. It is 
conceivable that combined T3/T4 therapy may result in smooth 24-Hour profile of both T3 as 
well as T4, as the peripheral deiodination of T4 is likely to provide continuous T3. On the 
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contrary, the half-life of T3 when used on its own is approximately 8-12 hours. The onset of 
action is quick and therefore it is possible that combined, once a day T3/T4 therapy could 
result in fluctuating T3 levels. The half-life of T3 when used in combination with T4 is not 
known. This was the rationale for our pharmacokinetic study designed to study the thyroid 
hormone levels over a 24-hour period on combined T3/T4 therapy. This study is likely to 
provide answer to the question “can T3 be given once a day when used as a part of combined 
T3/T4 therapy?” (publication 3). This was an important question, as slow release formulation 
of T3 is commercially not available, especially if combined T3/T4 therapy found useful. 
 
Methods: 
 
Twenty patients (10 patients on T4 alone and 10 patients on combined T3/T4 therapy) were 
randomly selected by the trial pharmacist, who was not in direct contact with the patients to be 
included in this pharmacokinetic study. This enabled the patients and the investigators to 
remain blinded. The patients had been on their study medication for a minimum period of 3 
months at the time of investigation. 7 patients in the T4 alone group and 8 in the T3/T4 group 
were on thyroxine for primary hypothyroidism. The rest were on thyroxine after having 
radioactive iodine treatment for thyrotoxicosis. All patients were given written and verbal 
instructions to take all their study medication at 8.00 AM for a week prior to their 24-hour 
profile study. On the day of the study, baseline blood sample was taken at 8.00 am and 
subjects then took their study medication under supervision. Eleven more blood samples were 
collected at 0900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 0600 and 0800 hrs over 
the next 24-hours. Patients were ambulatory with normal daily activity although strenuous 
exercise was avoided. Subjects slept between 2200hrs and 0600hrs and the final blood 
sample was collected at 0800hrs on the following day. Eleven patients (T3/T4:T4=6:5) not on 
beta blocking or anti hypertensive drugs attended on a second occasion for monitoring of their 
24-hour ambulatory blood pressure (BP) and pulse rate. Similar instructions were given prior 
to their attendance and the monitor was attached to the patients immediately after taking their 
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study medication. Thyroid function was monitored for the first 6 hours (5 samples at 0,1,2,4,6 
hours post-dose). Patients’ BP and pulse rate were monitored at the following intervals: half-
hourly for the first 6 hours post-dose, hourly for the next 8 hours and then 2 hourly (at night 
time) until the following morning. Patients returned home after the first 6 hours and were 
advised to avoid strenuous exercise and take rest for at least 5 min before and during each 
BP measurement. All the blood samples were stored overnight at 4C and then centrifuged. 
The serum was then stored below " 70C for later analysis. All the samples were analysed for 
TSH, free T4 and free T3 levels. 
 
Results: 
 
The thyroxine dose at the entry to the main study was similar between the 2 sub-groups. 
Baseline mean fT3 levels were similar between the 2 groups (T3/T4:T4 = 4.38:4.69 pmol/L, p 
= 0.208; range – T3/T4:T4 = 3.5– 5.2: 4.1–5.6) but as expected the baseline mean fT4 was 
lower (T3/T4: T4 = 12.05:17.9 pmol/L, p = 0.0001) and median TSH was higher (T3/T4:T4 = 
3.5:0.7 U/L, range – T3/T4:T4 = < 0.01,15.3: < 0.01,2.7, p < 0.001) as a result of T3 
substitution in the combined T3/T4 group.  
 
In patients on T4 alone, a modest 16 % rise in fT4 levels peaking 2–4 hours post-dose was 
seen, with higher levels for 12–16 hours. No rise (indeed a slight fall) in fT3 levels was seen. 
However, in the T3/T4 group mean fT3 levels showed a marked 42% rise within the first 4 
hours of medication ingestion, remaining above baseline for 16 hours and higher than the T4 
alone group for 22 hours. The mean fT3 levels at 4 hours post-dose (T3/T4:T4=6.24:4.63 
pmol/L, p=0.0007) as well as the overall area under the curve (AUC) were significantly higher 
in the T3/T4 group than the T4 alone (AUC: T3/T4: T4 = 1148:1062, p < 0.0001). 3 patients in 
the T3/T4 group but none in the T4 alone had fT3 levels above the laboratory reference range 
at some time over the 24-hour period. However these higher levels lasted only for a maximum 
of 2 hours. Despite greater T3 exposure in the T3/T4 group, this appeared not to alter the 
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pattern of TSH secretion. A similar circadian rhythm with a nocturnal rise persisted in both 
groups. 3 patients in the T3/T4 group and none in the T4 alone had a mean TSH higher than 
the lab normal range. One patient in the T3/T4 and 2 in the T4 alone had a suppressed TSH 
level throughout the 24-hour period. 
Figure 4: Mean % change and actual levels of thyroid hormones over a 24-hour profile 
Fig 4a       Fig 4b 
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as well as the overall area under the curve (AUC) were signifi -
cantly higher in the T3 / T4 group than the T4 alone (AUC: T3 / T4:
T4  =  1148:1062, p  <  0.0001). 3 patients in T3 / T4 group but none 
in the T4 alone had fT3 levels above the laboratory reference 
range at some time over the 24-hour period. However these 
higher levels lasted only for a maximum of 2 hours. 
 TSH values 
 Despite greater T3 exposure in the T3 / T4 group, this appeared 
not to alter the pattern of TSH secretion. A similar circadian 
rhythm with a nocturnal rise persisted in both groups ( ! "  Figs. 
 1 c,  2 c ). 3 patients in the T3 / T4 group and none in the T4 alone 
had a mean TSH higher than the lab normal range. One patient 
in the T3 / T4 and 2 in the T4 alone had a suppressed TSH level 
throughout the 24-hour period. 
 Pulse and BP changes 
 In the patients who attended for cardiovascular parameter anal-
ysis (n  =  11, T3 / T4:T4  =  6:5), no difference was apparent in the 
24-hour variation of the BP and pulse rate between the 2 groups 
 Table 1  Baseline Characteristics 
 Group  Age (yrs)  Number of 
Females 
 Number of 
primary Hypo 
 Pre WATTS T4 
dose (mcg) 
 Baseline Values 
      fT3 (pmol / L)  fT4 (pmol / L)  MedianTSH 
(mU / L) 
 T4 Alone 
(n  =  10) 
 62.39  4  7  127.5  4.69  17.9  0.7 
 T3 / T4 (n  =  10)  54.29  7  8  126.25  4.38  12.05  3.5 
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 Figure 1   a – c Mean values for free 
T3 ( a ), free T4 ( b ) and TSH ( c ) over the 
24-hour period. Error bars show standard 
errors (SEM) for each value. (Normal 
ranges: Free T3: 2.8 – 7.1  pmol / L; Free T4: 
10.0 – 24.0  pmol / L; TSH: 0.3 – 4.0  mU / L) 
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( Table 2 and  ! "  Fig. 3 ). No post-dosing peak in heart rate or blood 
pressure that differed between the groups was discernable and 
both groups sh wed similar ight-time falls in cardiovascular 
parameters. Thyroid function tests taken on this occasion for the 
fi rst 6 hours showed similar changes to those seen at the fi rst 
visit ( ! "  Fig. 4 ). 
 Discussion 
 & 
 This study demonstrates that after more than 3 months on once 
daily combined T3 (10  ! g) plus T4 therapy, subjects continue to 
show wide peak-to-trough fl uctuations in serum fT3 levels over 
a 24-hour period. The pharmacokinetics of T3 in combination 
therapy in which T3 is also being continuously generated from 
T4 therefore appears similar to that of T3 alone in hypothyroid 
patients and no adaptation to chronic therapy appears to occur 
( Saberi and Utiger, 1974 ). A recent study examined pharmacoki-
netic changes over a more limited period (the fi rst 9 hours post-
dose) and reported similar results ( Hennemann et al., 2004 ). We 
have additionally been able to observe that although excess fT3 
exposure persists for 16 hours post-dose, no effect on TSH diur-
nal rhythm or pulse or blood pressure variation was discerni-
ble. 
 These observations have several important clinical implications. 
Firstly, any interpretation of total or free T3 estimations on com-
bined therapy must take into account the timing of sampling in 
relation to dose. Indeed, no single value of fT3 can be used to 
refl ect the 24-hour profi le and isolated fT3 measurements can-
not be used for fi ne titration of T3 doses on once daily therapy. 
In the study of Bunevicius  et al advocating combined therapy, 
fT3 levels were measured 2 hours post-dose, and as a result were 
signifi cantly higher than on T4 alone. Where pre-dose levels 
were measured ( Bunevicius et al., 2002 ;  Siegmund et al., 2004 ; 
 Walsh et al., 2003 ) the levels are observed to be little different 
from T4 alone. This can erroneously lead to the conclusion that 
overall T3 exposure is similar when in fact the area under the 
curve for fT3 is higher on combination therapy. 
 Secondly, our observations lead us to reconsider which features 
of the thyroid hormone profi le on replacement therapy are most 
important. Despite a 42  % rise in fT3 over the fi rst 4 hours, no 
signifi cant changes in cardiovascular parameters were apparent 
Mean % Change - Free T3
-20
-10
0
10
20
30
40
50
0.00 4.00 8.00 12.00 16.00 20.00 24.00
Hours Post - Dose
Hours Post - Dose
Hours Post - Dose
%
 C
h
a
n
g
e
%
 C
h
a
n
g
e
%
 C
h
a
n
g
e
T3/T4
T4 Alone
T3/T4
T4 Alone
T3/T4
T4 Alone
Mean % Change - Free T4
-10
-5
0
5
10
15
20
0.00 4.00 8.00 12.00 16.00 20.00 24.00
Mean % Change - TSH
-40
-30
-20
-10
0
10
20
30
0.00 4.00 8.00 12.00 16.00 20.00 24.00
a
b
c
 Figure 2   a – c Mean values for the percentage 
change from baseline (time  =  0) in free T3 ( a ), free 
T4 ( b ) and TSH ( c ) over the 24  h period. Error bars 
show standard errors (SEM) for each value. 
 
Figure 4a: a–c Mean values for free T3 (a), free T4 (b) and TSH (c) over the 24-hour period. Error bars 
show standard errors (SEM) for each value. (Normal ranges: Free T3: 2.8–7.1 pmol/L; Free T4: 10.0–
24.0 pmol/L; TSH: 0.3–4.0 mU/L) 
Figure 4b: a–c Mean values for the percentage change from baseline (time = 0) i  fr e T3 (a), fr e T4 
(b) and TSH (c) over the 24 h period. Error bars show standard er ors (SEM) for each value. 
 
In the patients who attended for cardiovascular parameter analysis (n = 11, T3/T4:T4 = 6:5), 
no difference was apparent in the 24-hour variation of the BP and pulse rate between the 2 
groups. No post-dosing peak in heart rate or blood pressure that differed between the groups 
was discernable and both groups showed similar night-time falls in cardiovascular parameters.  
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Summary & significance of this publication: 
 
In summary, we have confirmed that wide peak-to-trough variation in fT3 levels persist in once 
daily combination therapy with T3 and T4 after more than 3 months treatment. This variation 
makes interpretation of thyroid function tests on combined therapy more difficult as basal fT3 
levels may underestimate total T3 exposure and peak fT3 levels may overestimate it. 
Furthermore, TSH levels cannot be used to indicate overall exposure to T3 as levels rose 
when T3 was substituted for T4 despite increased T3 levels. Thus, the pharmacokinetics of T3 
in combination therapy in which T3 is also being continuously generated from T4 appears 
similar to that of T3 alone in hypothyroid patients and no adaptation to chronic therapy 
appears to occur (32). These observations have other important clinical implications. Firstly, 
our observations lead us to reconsider which features of the thyroid hormone profile on 
replacement therapy are most important. The baseline TSH levels rose on T3/T4 therapy 
despite a 42% rise in fT3 over the first 4 hours. There were no significant changes in 
cardiovascular parameters and patients did not appear to notice any particular symptoms over 
this period or report diurnal variation in symptoms as often reported on hydrocortisone 
replacement in hypoadrenalism (33, 34). Secondly, our observations raise the issue of the 
correct dosing interval for T3 on combined T3/T4 therapy. Even though we did not 
demonstrate any significant differences in the cardiovascular parameters, it would be logical to 
use a twice or three times daily dosing which may achieve smoother 24-hour T3 levels that 
resemble individuals with an intact thyroid axis more closely (35).  
 
This was the first and only study to date to show the pharmacokinetics of thyroid hormones 
over a 24-hour period on combined T3/T4 therapy. The role of combined T3/T4 in thyroid 
hormone replacement remains controversial (36, 37). Many practitioners continue to use this 
combination (30, 31) and our own results in a large population are consistent with possible 
benefit in a subgroup of individuals (38). If a role is confirmed for combination therapy, it will 
be important to resolve the pharmokinetic issues raised by the current study in order to 
 24 
achieve safe and optimal dosing. An alternative possibility is the formulation of a slow release 
T3. Hennemann et al recently showed that their in-house “slow release” version of T3 when 
used with T4 gives a smoother profile than the standard T3 for at least 9 hours post-ingestion 
(39). However, such slow release formulation is not currently available. In the mean time, it 
would be sensible to use both pre and 2 hours post dose levels of thyroid hormones for those 
on combined T3/T4 therapy. 
 
Project 4 – Correlations of thyroid hormones and wellbeing (publication 4): 
 
Introduction: 
 
The occurrence of various abnormalities in brain function including cognitive and memory 
impairment in patients with overt hypothyroidism is now well established. Reduced levels of 
thyroid hormone appear to slow serotonergic neurotransmission in the brain (40), an effect 
associated with low mood. In addition, thyroid hormones are widely used to augment 
antidepressant treatment (41), although the trial evidence underlying this is controversial (42). 
Evidence for lesser variation in thyroid hormone levels affecting mood and psychological well-
being remains more controversial. Some cross-sectional studies suggested that subclinical 
thyroid dysfunction is associated with depression, cognitive impairment, and memory loss 
(reviewed in (43). Carr et al. (10) reported that patients receiving thyroid hormone 
replacement appeared more content on higher doses of T4. The large HUNT (Nørd-Trondelag 
Health Study) community-based study failed to find an association, but the correlations were 
made with categories of TSH level rather than using T4 and TSH, as continuous variables. 
Interestingly, in the subgroup of patients on T4, a link with depression was reported (44). 
Including our study, several studies of thyroid hormone replacement therapy reported that the 
combination of T3/T4 is not superior to T4 alone. However, where thyroid hormone levels 
were raised, psychological well-being appeared to have improved (29). 
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In view of the large body of circumstantial evidence linking thyroid hormone levels and mood 
and the relative stability of endogenous thyroid hormone levels within a given individual over 
time (45, 46), we hypothesized that variation in thyroid hormone levels, even within the 
laboratory reference range, might represent an independent risk factor for low mood and 
depression. My fourth project was to test this hypothesis, by examining the relationship 
between thyroid hormone parameters and psychological well-being across a large cohort of 
patients (n=697) treated with T4 whose thyroid functions are in the laboratory normal range 
(publication 4). 
 
Methods: 
 
Baseline data from our large prospective study was used for this study. Patients’ well-being 
was assessed at study entry by the General Health Questionnaire (GHQ)-12, which is a well-
validated tool in predicting morbidity when compared with complex psychometric tests and 
detailed interview. The GHQ-12 has four responses for each question: “better than usual,” 
“same as usual,” “less than usual,” and “much less than usual.” In addition to the GHQ- 12, all 
subjects completed the Hospital Anxiety and Depression Scale (HADS) and an un-validated 
questionnaire, the Thyroid Symptom Questionnaire (TSQ) based on symptoms frequently 
reported by patients on thyroid hormone. All the questionnaires were scored both by the Likert 
(linear) and categorical scoring methods as described earlier. At the study entry, blood was 
drawn and stored for measurement of thyroid hormones and all the samples were analyzed as 
a single batch at the end of the study. The normal ranges were: serum TSH (NR 0.3– 4.0 U/l), 
free T4 (NR 10.0 –24.0 pmol/liter), free T3 (NR 2.8–7.1 pmol/liter) serum reverse T3 (rT3) (NR 
0.14–0.34 nmol/liter) and anti-thyroid peroxidase (TPO) antibodies (+ve titre - >100). The 
relationships between psychological questionnaire scores and serum thyroid hormone 
measurements were ascertained using linear and logistic regression analyses for continuous 
and binary versions of the questionnaires, respectively. Multiple regression analysis was used 
when adjusting for age, sex, and anti-TPO antibody positivity. 
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Results: 
 
The mean age of the patients was 57.3 yrs. Eighty-four percent of patients were women 
(n=586). The causes of hypothyroidism were autoimmune hypothyroidism (73.45%), post-
radioactive iodine (9.33%), post thyroidectomy (15.78%), and post-thyroidectomy & post-
radioactive iodine (1.44%). Forty-four percent of the patients (n=307) had a strongly positive 
titer for anti-TPO antibodies (titer>100).  
 
Baseline fT4 showed a strong negative correlation to the GHQ-12 scores (correlation 
coefficient b: -0.155, p=0.005). The relationship persisted even after correcting for age, sex, 
and anti-TPO antibody positivity (b: -0.14, p=0.015) and was also present in the subset of 
patients with TSH between 0.3 and 4.0 IU/liter (b: -0.159, p=0.038, n=473). The same 
correlations were observed when the GHQ was scored as a categorical parameter (GHQ 
scoring). The relationship was in the expected direction (higher fT4 associated with lower 
GHQ scores implying improved well-being), and the slope indicated an improvement of 1 
GHQ point for a 0.51 ng/dl (6.5 pmol/ liter) rise in fT4. A positive correlation was seen with log 
TSH and GHQ [b: 0.66, p=0.04; no change after controlling for age, sex, and anti-TPO 
antibody positivity (b: 0.68, p=0.04)]. This correlation was preserved in the subset of patients 
with TSH in the range 0.3–4.0 IU/liter (b: 2.3, p=0.006). In contrast, no correlation was seen 
among fT3, rT3 , rT3 to T4 and T3 to rT3 ratios, and anti-TPO positivity and GHQ scores. 
Similar results were observed with the TSQ. FT4 showed significant correlation with both the 
linear (correlation coefficient b: -0.11, p=0.03) and categorical scores of TSQ, and this 
persisted in the TSH 0.3–4.0 IU/l subset. Whereas no correlation was seen between linear 
TSQ and log TSH (b: 0.09, p=0.41), a relationship was seen between the categorical TSQ and 
log TSH (OR 1.4, p=0.007) but was lost in the TSH 0.3– 4.0 IU/l subset. Similar to GHQ, no 
other correlation was seen between TSQ and any other thyroid hormone parameters. No 
correlation was seen among any of the thyroid hormone parameters and the anxiety and 
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depression scales of the HADS (data not shown) with the exception of log TSH and HADS 
depression as a continuous variable (b: 0.562, p=0.004). However, this relationship was not 
seen when HADS depression score was used as a categorical variable (OR 1.2, p=0.54). 
 
In the subgroup of patients with fT4 level above the reference range, no correlation between 
psychological well-being and the fT4 levels seen using regression model. However, the mean 
GHQ scores are significantly lower (improved well being) in this group as a whole, compared 
with the subgroup of patients with levels of thyroid hormones in the reference range (high fT4 
vs. normal fT4: 12.33+4.79 vs. 13.72+5.45, p=0.007). By the categorical scoring method, the 
percentage of caseness was also less in patients with high fT4 levels (35.1 vs. 45.3%, 
p=0.03). Similar results were seen in TSQ scores (linear TSQ scores: high fT4 vs. normal fT4: 
13.91+4.66 vs. 14.85+4.88, p=0.04; percent caseness: high fT4 vs. normal fT4: 56.1 vs. 
66.0%, p=0.03). Similar post hoc analysis of patients according to anti-TPO antibody status 
did not show any significant difference in GHQ between anti-TPO-positive and negative 
patients (anti-TPO positive vs. anti-TPO negative: 13.71+5.42 vs. 13.12+5.26, p=0.147). 
Similar results were obtained when antibody status was used as an interaction factor in the 
regression model. 
 
Summary & significance of this publication: 
 
This is the first large study to explore the relationship between fT4, fT3, rT3 and the ratios of 
T3/rT3 & rT3/T4 with psychological well-being in subjects on thyroid hormone replacement. 
Improved psychological well-being was found to correlate with higher fT4 levels. The 
significance of the observation is supported by the finding of a relationship between 
psychological well-being and TSH with the opposite slope (higher TSH with reduced well-
being as might be expected). A similar relationship with fT4 was found with an un-validated 
score of symptoms that relates more directly to thyroid status (TSQ) making a false positive 
association due to multiple testing less likely. Interestingly, no clear association was seen with 
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the HADS scale, which may suggest that the thyroid function influences parameters of 
psychological well-being not typical of anxiety or depression. TSH is often considered the 
most sensitive measure of thyroid function. However, it appears that the relationship between 
well-being and fT4 was as much if not more pronounced as with TSH. TSH levels reflect 
hypothalamopituitary sensing of circulating thyroid hormone levels, which may be different 
from thyroid hormone status in other tissues and the importance of fT4 measurement in 
addition to or distinct from serum TSH estimation to assess thyroid status has been 
emphasized by our study. Similarly, studies in pregnancy, maternal hypothyroxinemia in the 
first trimester and not raised TSH was associated with impaired psychomotor development in 
offspring (47), and fT4 but not TSH at 9 wk of pregnancy is directly proportional to the birth 
weight of the offspring (48). The failure to find a relationship between serum fT3 and 
GHQ/TSQ scores is also of interest. Many thyroidologists consider the T3 assay to be less 
technically reliable and less reflective of thyroid status, particularly in the hypothyroid range 
(49). Although T3 is the active hormone, free concentrations of T4 are five times higher, and 
many tissues obtain 30% or more of their intracellular T3 directly from circulating T4 (6). 
Hence, circulating T3 levels may not be directly reflective of intracellular levels. We measured 
serum rT3 levels as a possible measure of intracellular deiodinase activity (6, 50). The failure 
of rT3 levels or ratios with thyroid hormones to correlate with psychological well-being might 
relate to serum levels being more indicative of hepatic D1 and D2 activity, whereas 
intracellular levels are strongly influenced by local levels of membrane-bound deiodinases 
including D2 and D3 (6, 51). Our findings provide the only support for the view that serum fT4 
levels as well as TSH levels should be taken into account when adjusting dosages and that 
TSH may not be a perfect indicator of the adequacy of replacement, particularly with regard to 
psychological well-being. However, large population-based studies of thyroid function 
parameters including fT4 and psychological well-being will be required to explore this further. 
This study provided the crucial pilot data for a later, large community based study by our 
group (DEPTH Study, ongoing).  
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Project 5: Identification of sub-group of hypothyroid patients who may have reduced 
psychological wellbeing on T4 alone therapy and respond better to combined T3/T4 
therapy (publication 5) 
 
Introduction: 
 
Several studies using different combination of T3/T4 therapy, including our large community 
based study failed to show convincing benefit of such therapy over T4 alone therapy. 
However, the reduced psychological wellbeing in patients on thyroid hormone therapy has 
been confirmed by other studies in addition to our large cross-section study (project 1). 
Anecdotally several patients feel better on combined therapy. In addition, at least 2 of the 
combined T3/T4 studies suggest there may be a sub-group of hypothyroid patients who may 
respond better to such therapy. Indeed, if the sub-group represent <20% of the population, 
such patients may be too infrequent for their presence to be detected in the intervention trials 
but could still account for significant morbidity in patients on thyroxine therapy. Our hypothesis 
is that such sub-group has inherited abnormality that becomes clinically significant only when 
they become hypothyroid. The 3 deiodinase enzymes (D1, D2 & D3) represent possible 
candidate loci for such genetic variation. Our study (publication 2), the largest to date, 
provided an opportunity to explore this hypothesis. We studied the role of the common 
polymorphisms in the 3 deiodinase genes in determining the psychological well-being of 
patients on T4 alone therapy and the response to combined T3/T4 replacement. 
 
Methods: 
 
Out of the 697 participated in the original randomised controlled trial (project 2), 552 subjects 
provided their blood for extracting DNA. We used genotype data from the Caucasian 
European individuals in the International Haplotype Mapping Project (http://www.hapmap.org) 
to select a set of SNPs that capture the majority of common variation across the three 
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deiodinase genes (DIO1, DIO2, and DIO3) including 50 kb either side of the genes. We used 
a minor allele frequency of at least 10%. The 21, seven, and seven SNPs in the DIO1, DIO2, 
and DIO3 genes required nine, four, and six SNPs, respectively, to capture all common 
variants with an r2 >0.8. These were: DIO1, rs11206237, rs11206244, rs2235544, rs2268181, 
rs2294511, rs2294512, rs4926616, rs731828, and rs7527713; DIO2, rs12885300, rs225011, 
rs225014, and rs225015; and DIO3, rs1190716, rs17716499, rs7150269, rs8011440, 
rs945006, and rs1190715. We used only SNPs that were in Hardy Weinberg equilibrium 
(p>0.05) and were genotyped in at least 97.5% of the samples in the final analyses. We 
examined the association between these SNPs and baseline (before randomization) 
psychological well-being by linear regression analysis (GHQ Likert score as dependant 
variable and genotype as independent variable). Repeated measures ANOVA was used to 
detect the response to therapy with treatment arm (T4 alone or T3/T4) and genotype were the 
between-subject effects. Baseline scores were adjusted for as covariates and included two-
way interactions between treatment arm & genotype and genotype & baseline score. 
 
Results: 
 
Effect on psychological well-being: 
 
Out of the 16 SNPs studied, only 2 SNP in the DIO1 gene (rs225014, rs225015) showed an 
association at p<0.05 level of significance. Because the two DIO2 SNPs are in strong linkage 
disequilibrium with an r2 of 0.88 in this population, and rs225014 is also in linkage 
disequilibrium with the third SNP studied in this gene, rs225011 (r2 of 0.59), further analysis is 
done only on rs225014 alone. In this SNP, each C allele (TT, TC, CC) was associated with an 
average increase of 0.71 GHQ points (worse well-being, p for trend = 0.02; exactly the same 
difference observed in our cross-sectional study – project 1). HADS depression score showed 
similar association reaching significance (p=0.01) and the others showed trend in the same 
direction without reaching statistical significance. Interestingly, this SNP did not have any 
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detectable effect on thyroid functions suggesting this effect may be independent of serum 
thyroid hormone levels.  
 
Effect on response to therapy: 
 
There was significant interaction between treatment arm and genotype on improvement in 
GHQ (p=0.03), TSQ (p=0.03) and satisfaction scores (p=0.02). This suggests an improved 
response to combined (T3/T4) therapy in this genotype (rs225014). This is the same sub-
group who had the poorest psychological well-being at baseline (on T4 alone therapy). In the 
CC genotype, the mean improvement in GHQ score was 2.33 (95% CI: 0.38, 4.38) at 3 
months and 1.44 (95% CI: -0.25, 3.12) at 12 months with combined T3/T4 therapy. The 
rs225014 genotype frequencies were not significantly different between the study groups 
(frequency of TT, TC, and CC genotypes: 40.6, 45.5, and 13.9%, in T4 /T3 group and 41.1, 
41.1, and 17.9% in T4 only group, p=0.38). The prevalence of minor homozygous (CC) of the 
rs225014 is 14.1% in the overall cohort, confirming our initial hypothesis that if there is a small 
sub-group, they may not be detectable in the intervention trials. Indeed, despite being the 
largest study, we would estimate that only around 50 subjects would have had this genotype 
in the intervention group, who would respond to combined therapy. Given the large placebo 
effects seen, the differential change in these subjects was not detected in the initial analysis of 
the whole cohort. 
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Figure 5: Response to therapy by genotype (rs225014 vs. GHQ, TSQ & satisfaction) 
effect was suggested by the graphs (Fig. 1) and has been proposed pre-
viously (29). For satisfaction score, no baseline score was adjusted for
because there was no baseline assessment. No correction was made for
multiple testing because, despite being the largest study to date, it is still
underpowered to detect all but very large differential gene-treatment
effects. Instead, we have chosen to report the P values and associations,
which should be considered suggestive, and have qualified our findings
by stating clearly that the results need replicating as a risk of type I
statistical error exists. Analyses were performed on Stata version 9.0
(www.stata.com) and SPSS version 14.0 (www.spss.com).
Results
Descriptive statistics of the two groups are displayed in Table 1.
The treatment groups were not significantly different at baseline
in any of the parameters studied.
Genotype and psychological well-being
at baseline
The relationship between the 16 SNPs
covering the three deiodinase genes and
baseline psychological well-being is shown
in Table 2. Two SNPs in the DIO2 gene;
rs225014 and rs225015 showed an associ-
ation at theP!0.05 level of significance. By
contrast, theother SNPsanalyzed, including
all of those from DIO1 and DIO3 did not
show any association. Because the two D2
SNPs that had showed an association,
rs225014 and rs225015, are in strong link-
age disequilibrium with an r2 of 0.88 in this
population, and rs225014 is also in linkage
disequilibriumwith the third SNP studied in
this gene, rs225011 (r2 of 0.59), further
analysis is shown on rs225014 alone. In this
SNP the possible base combinations of thy-
mine (T) and cytosine (C) are TT, TC and
CC. ForGHQ-12, eachCallele of rs225014
was associated with an average increase of
0.71 GHQ points (worse well-being, P for
the trend" 0.02) with a difference between
the CC and TT alleles of 1.3 points.
Table 3 shows the relationship between
rs225014 genotype and baseline psycholog-
ical well-being for other parameters mea-
sured in WATTS. The scores for GHQ-12
from Table 2 are included for comparison.
An association with HAD-D (depression)
caseness in the same direction as GHQ was
seen (P"0.01). EachCallelewas associated
with a 49% increase in odds of being a
HAD-D case (P" 0.01) and as a result case-
ness was almost twice as great in subjects
homozygous for the CC genotype as in sub-
jectswith theTT genotype (24 vs. 13%).No
significant differenceswere seen in the other
psychological scores, although all the scores
appeared to increase in the same direction
across the genotypes (Table 3), with the TT
genotype having the lowest score and TC intermediate and CC
the worst score. We published previously that rs225014 did not
have any detectable effect on baseline thyroid function in this
cohort, and hence, this effect appears to be independent of serum
thyroid hormone levels (30).
Genotype and response to therapy
Results of repeated-measures ANOVA for response to treat-
ment by genotype and treatment arm for rs225014 are shown in
Fig. 1.P values indicate an effect of an interaction between treat-
ment arm (T4/T3 vs. T4) and the CC genotype on mean scores at
both follow-up visits. Note the higher baseline scores for GHQ
in theCCgenotype as inTable 2.As described in the initial report
(18), both treatments resulted in an improvement from baseline
consistentwith a strong placebo effect.However,when analyzed
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FIG. 1. Response to therapy by genotype rs225014 as measured by GHQ (A), TSQ (B), and satisfaction
score (C). Squares and continuous line, T4/T3 group; triangles and dashed line, T4-only group. P values
reflect the significance of an effect of the CC genotype on difference in scores by treatment arm using
repeated-measures ANOVA. *, P ! 0.05. There was a significant effect of the interaction between the CC
genotype and treatment arm at follow-up (visits 2 and 3) on GHQ scores, TSQ scores, and satisfaction.
There are no baseline (visit 1) scores for satisfaction with therapy (C) because this was not assessed at
baseline. For GHQ and TSQ scores, higher scores indicate worse well-being, whereas for satisfaction higher
scores indicate more satisfied.
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Summary & significance of this publication: 
 
Our study is the only study to show the potential presence of a sub-group of patients (DIO2 
gene SNP rs225014) who are dissatisfied with T4 alone therapy. Our study also showed that 
this sub-group of hypothyroid patients may respond better to combined T3/T4 therapy. We 
studied 16SNPs across 3 genes. Though our study is the largest T3/T4 trial available, it is still 
underpowered to reliably detect gene-treatment interaction. However, if replicated, it has huge 
implications for a large number of patients on thyroid hormone replacement therapy 
(estimated around 1.5 million people in the UK alone). This is likely to reflect an effect on 
local, tissue level deiodination of T4 by D2 in the brain as this do not have any effect on 
circulating thyroid hormone levels. Our observation that common genetic variation in the DIO2 
gene but not the DIO1 or DIO3 genes could be relevant to psychological well-being is 
interesting because the D1 enzyme is not expressed in the brain and D3 is a deactivating 
enzyme. Therefore, D2 is the only enzyme able to convert T4 to T3 in the brain and is likely to 
play a key role in determining the ability of the brain to respond to circulating T4 levels. 
Indeed, common variation in D2 activity may represent the best available marker of 
intracellular T3 levels in the brain. The lack of effect of the DIO2 polymorphisms on serum 
thyroid hormone levels means that without performing genetic testing, it is impossible to select 
out the group likely to respond to combination therapy for subgroup analysis in intervention 
trials.  
 
Other publications: 
 
Publication 6&7: Whose thyroid function is normal – yours or mine? 
 
Until recently, endocrinologists believed that thyroid hormone is the easiest hormone to 
replace. Treated hypothyroid patients thyroid hormone replacement is determined by their 
TSH. Traditionally, “normal or reference ranges” are derived either using epidemiological data 
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or using statistical method. The statistical method is the most commonly used as it is the 
easiest and in the absence of epidemiological data associating with outcomes. Such reference 
range is generally 2 standard deviations above and below the mean of apparently “disease-
free” individual. As nearly 10% of the population might have sub-clinical thyroid disease, such 
reference range will therefore have limitations. Indeed, a 20-year longitudinal Wickham survey 
indicated that individuals with TSH values >2.0IU/l have increased risk of developing overt 
hypothyroidism over the next 20 years (3). An elegant study by Andersen et al showed that 
individuals’ TSH revolves around a “set point” and there is a significant inter-individual 
variation (45). The variation for an individual is much narrower than the laboratory reference 
range. Our invited commentary highlighted the potential of being hypothyroid of a given 
subject despite their TSH in the “normal range”. This also highlighted the importance of 
measuring the “relative change” in TSH along with clinical symptoms in considering initiating 
treatment with thyroid hormone replacement therapy. 
 
Publication 8: Understanding thyroid hormone actions: A review 
 
Following the publication of our initial work (cross-section study, publication 1) and the 
subsequent large randomised trial (publication 2), several other groups throughout the world 
published works highlighting the relative complexity of thyroid hormone action. Several steps 
are involved from the time the thyroid hormones are released in the serum and the time of its 
action on the nuclear receptors. Thyroid hormones are taken into the cell by transporters, 
converted to its active metabolite by deiodinase enzymes before it exerts its function on 
nuclear receptors. There were also novel findings about actions of thyroid hormone 
transporters and the potential consequences of mutations involving such transporters. 
Understanding the complexity has opened a new avenue for further research in this area. This 
was comprehensively reviewed by us (publication 7) providing insights in the potential 
mechanisms of “euthyroid dysphoria”. 
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Publication 9: Variation in deiodinase gene polymorphisms and thyroid hormone 
levels: 
 
It is known that genetic factors influence circulating thyroid hormone levels. However, until 
recently the common genetic variants influencing the levels has not been identified. Data from 
our large randomised trial on hypothyroid patients (publication 2) was used to thoroughly 
examine the role of common variation across the three-deiodinase genes in relation to 
circulating thyroid hormones. The findings from our cohort (n=552) were taken forward to 
three other cohorts in people not on thyroid hormone replacement therapy (n=2513). The 
results showed an SNP in the DIO1 gene (rs2235544) was associated with T3/T4 ratio with 
genome-wide level of significance (p=3.6x10-13). The C-allele of this SNP was associated with 
increased T3/T4 ratio and T3 levels and decreased T4 and rT3 levels. There was no effect on 
TSH levels. Thus, this study provided the first evidence that common genetic variation in D1 
gene alters type 1 deiodinase function resulting in alteration in the balance of circulating T3 
and T4 levels. This finding will therefore provide a valuable tool to assess the relative effects 
of circulating T3 and T4 levels on a wide range of biological parameters. 
 
Publication 10: What is the optimal thyroid hormone replacement? 
This invited editorial was written to practicing general practitioners and clinicians, reviewing 
the latest evidence on thyroid hormone replacement therapy and provides guidelines on 
deciding thyroid hormone replacement therapy for patients with hypothyroidism. This paper 
also provided simple algorithm for treating hypothyroid patients. 
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